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COMMENTARY
Lessons from an Evidence-Based Medicine Exploration: 
When Transparency and Sensitivity (Analyses) Can Change 
the Take-Home Message
Nadi N Kaonga, MD, MHS, MS,1 Toby Fitzgerald, DO1
1Department of Obstetrics and Gynecology, Maine Medical Center, Portland, ME
BACKGROUND
Induction of labor is quite common in the United 
States. While induction rates have declined over 
the last decade, nearly 1 in 4 deliveries (23%) in 
the United States is induced for medical or elective 
reasons.1 Of the induction agents available, 
intravenous (IV) oxytocin is used in an estimated 
25% of cases.2 At our academic medical center, 
40% of our labor inductions from April 2019 to 
September 2019 used IV oxytocin (unpublished 
data). This medication comes with high risks, 
including uterine tachysystole, hyperstimulation, 
fetal distress, hypotension, hypertension, 
hyponatremia, seizures, and coma.2
To understand our use of IV oxytocin and its impact 
on birth outcomes at our institution, we conducted 
a literature search and discussed the findings 
in our department’s evidence-based medicine 
(EBM) session (ie, journal club). We identified 4 
recent articles that performed systematic reviews 
evaluating birth outcomes and use of IV oxytocin. In 
particular, the articles examined how discontinuing 
IV oxytocin during the active phase of labor impacts 
the cesarean section (C-section) rate.2,3-5 While all 
4 review articles concluded that discontinuing IV 
oxytocin in the active phase of labor significantly 
reduced the C-section rate, 1 article conducted 
sensitivity analyses that, importantly, changed 
the interpretation of the primary outcome.2 With 
this new interpretation, we identified important 
considerations when reviewing the literature. In 
this article, we share our lessons from our EBM 
exploration on this topic to help inform more 
rigorous and creative approaches to interpreting 
the literature.
LESSONS
Know your resources and think outside of the 
box
In our Department of Obstetrics and Gynecology, 
our method for EBM literature reviews is to first 
identify a faculty mentor and also consider meeting 
with the department’s research navigator. The 
research navigator has a background in research 
methods, biostatistics, and epidemiology. Given 
their skillset, they serve as a resource to better 
understand the clinical literature. Our department’s 
research navigator helped explain and clarify the 
more advanced statistical concepts in the review 
articles. In our process, they also encouraged non-
traditional thinking and prompted our exploration 
of the supply and distribution of IV oxytocin at our 
institution.
In this pursuit, we spoke with the pharmacy and 
billing departments to better understand how IV 
oxytocin is acquired and distributed, and what it 
costs our institution and patients. To learn more 
and contextualize our center’s use of IV oxytocin, 
we worked with our department’s head of quality 
improvement to compile data and analyze births 
and inductions over a 6month period. This approach 
allowed us to conceptualize the review articles’ 
findings within our local context.
The research navigator, pharmacy staff member 
and billing representative supported the exercise, 
and their additional input helped to enrich the 
subsequent EBM discussion with practical cases 
and considerations. We were also able to supply 
evidence (albeit specific to our academic medical 
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center) that was otherwise missing from the global 
evidence base for discussion.
Read more than one article
For the purpose of our department’s EBM session, 
we selected 1 review article to focus on and discuss. 
While we had 1 article in mind, we conducted a 
cursory review in PubMed that helped identify 
4 similar review articles. Without this cursory review, 
we would not have found the article by Boie et al.2 
There was 78% to 100% overlap of references 
between the 4 review articles, and we were able 
to read the additional articles to compare methods 
and findings. This process revealed a crucial, yet 
overlooked, limitation and analysis in 3 of the review 
articles that ultimately changed the interpretation 
of the primary outcome. Boie and colleagues took 
these factors into consideration in their review.
Checklists and reporting guidelines are a 
helpful start
In 2 of the most recent 4 review articles,2,5 the 
Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) Checklist was used 
to guide the reading and appraisal of the articles.6 
Both articles accounted for all items within the text 
or supplementary files. However, only through 
closer reading and comparison did we understand 
how and why only Boie et al conducted sensitivity 
analyses in their review article.
Transparency matters
Boie and colleagues were very transparent in their 
reporting. They justified why they conducted specific 
types of analyses. Oftentimes, their analyses were 
limited by the level of reporting in the individual 
studies. Accordingly, they contacted authors of 
the individual studies to obtain as much detail as 
possible regarding the included data.
Sensitivity analyses can be game changers
Sensitivity analyses provide the ability to assess 
the robustness of a primary result and test how 
the results may or may not hold based on different 
assumptions.7 The sensitivity analysis conducted 
by Boie and colleagues revealed a critical omission 
in previous analyses of the primary outcome. While 
all the review articles concluded that the C-section 
rate was significantly reduced when IV oxytocin 
was discontinued during the active phase of labor, 
the sensitivity analysis in the Boie et al review only 
included data on C-sections after the active phase. 
By focusing only on these patients, they found 
that discontinuing IV oxytocin in the active phase 
of labor had little to no impact on the C-section 
rate. This finding underscores the importance of 
understanding assumptions and assessing data in 
different ways. Furthermore, the sensitivity analysis 
conferred a greater level of certainty (moderate) but 
only reflected data from 4 studies. When considering 
practice, this finding was now less influential, and it 
also resulted in closer critique and questioning of 
the findings for the secondary outcomes.
Additionally, IV oxytocin is a high-risk medication 
with several severe side effects. While its 
continuation minimally reduces the time from labor 
to delivery and its discontinuation does not impact 
the C-section rate, a risk-benefit analysis for each 
use case must be considered.
CONCLUSION
Ultimately, EBM discussions are meant to challenge 
and/or inform practice. The lessons learned from 
this EBM exploration are salient reminders that data 
reported in articles should not be blindly accepted. 
We hope that the lessons we shared in this article 
will serve as a helpful starting point and approach 
to more rigorous and creative EBM reflection and 
discussions.
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